Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...

Study researchers spotted the spike in liver enzymes, or liver transaminitis, among people who received BioAge’s drug either as monotherapy or in combination with tirzepatide, which Lilly sells as ...

Eli Lilly and Company announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain. — ­New clinical trial results on the diabetes ...

CHICAGO — ­New clinical trial results on the diabetes and obesity drug tirzepatide have doctors buzzing about its potential to treat heart failure, keep weight off and prevent type 2 diabetes.

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a weight-loss drug.